Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Hypertension Reports
Published in: Current Hypertension Reports 1/2012

01-02-2012 | Vascular Mechanisms (F Ruschitzka, Section Editor)

The Nox Family of NADPH Oxidases: Friend or Foe of the Vascular System?

Authors: Ina Takac, Katrin Schröder, Ralf P. Brandes

Published in: Current Hypertension Reports | Issue 1/2012

Login to get access

Abstract

NADPH (nicotinamide adenine dinucleotide phosphate) oxidases are important sources of reactive oxygen species (ROS). In the vascular system, ROS can have both beneficial and detrimental effects. Under physiologic conditions, ROS are involved in signaling pathways that regulate vascular tone as well as cellular processes like proliferation, migration and differentiation. However, high doses of ROS, which are produced after induction or activation of NADPH oxidases in response to cardiovascular risk factors and inflammation, contribute to the development of endothelial dysfunction and vascular disease. In vascular cells, the NADPH oxidase isoforms Nox1, Nox2, Nox4, and Nox5 are expressed, which differ in their activity, response to stimuli, and the type of ROS released. This review focuses on the specific role of different NADPH oxidase isoforms in vascular physiology and their potential contributions to vascular diseases.
Literature
1.
Lambeth JD. Nox enzymes, ROS, and chronic disease: an example of antagonistic pleiotropy. Free Radic Biol Med. 2007;43:332–47.PubMedCrossRef
2.
Bedard K, Krause KH. The NOX family of ROS-generating NADPH oxidases: physiology and pathophysiology. Physiol Rev. 2007;87:245–313.PubMedCrossRef
3.
Lassegue B, Sorescu D, Szocs K, et al. Novel gp91(phox) homologues in vascular smooth muscle cells: nox1 mediates angiotensin II-induced superoxide formation and redox-sensitive signaling pathways. Circ Res. 2001;88:888–94.PubMedCrossRef
4.
Sorescu GP, Song H, Tressel SL, et al. Bone morphogenic protein 4 produced in endothelial cells by oscillatory shear stress induces monocyte adhesion by stimulating reactive oxygen species production from a nox1-based NADPH oxidase. Circ Res. 2004;95:773–9.PubMedCrossRef
5.
Gorlach A, Brandes RP, Nguyen K, et al. A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circ Res. 2000;87:26–32.PubMed
6.
Chamseddine AH, Miller Jr FJ. Gp91phox contributes to NADPH oxidase activity in aortic fibroblasts but not smooth muscle cells. Am J Physiol Heart Circ Physiol. 2003;285:H2284–9.PubMed
7.
Ellmark SH, Dusting GJ, Fui MN, et al. The contribution of Nox4 to NADPH oxidase activity in mouse vascular smooth muscle. Cardiovasc Res. 2005;65:495–504.PubMedCrossRef
8.
Van Buul JD, Fernandez-Borja M, Anthony EC, et al. Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid Redox Signal. 2005;7:308–17.PubMedCrossRef
9.
Ago T, Kitazono T, Ooboshi H, et al. Nox4 as the major catalytic component of an endothelial NAD(P)H oxidase. Circulation. 2004;109:227–33.PubMedCrossRef
10.
Belaiba RS, Djordjevic T, Petry A, et al. NOX5 variants are functionally active in endothelial cells. Free Radic Biol Med. 2007;42:446–59.PubMedCrossRef
11.
Jay DB, Papaharalambus CA, Seidel-Rogol B, et al. Nox5 mediates PDGF-induced proliferation in human aortic smooth muscle cells. Free Radic Biol Med. 2008;45:329–35.PubMedCrossRef
12.
Cave A. Selective targeting of NADPH oxidase for cardiovascular protection. Curr Opin Pharmacol. 2009;9:208–13.PubMedCrossRef
13.
Hilenski LL, Clempus RE, Quinn MT, et al. Distinct subcellular localizations of Nox1 and Nox4 in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2004;24:677–83.PubMedCrossRef
14.
Hanna IR, Hilenski LL, Dikalova A, et al. Functional association of nox1 with p22phox in vascular smooth muscle cells. Free Radic Biol Med. 2004;37:1542–9.PubMedCrossRef
15.
Kuroda J, Nakagawa K, Yamasaki T, et al. The superoxide-producing NAD(P)H oxidase Nox4 in the nucleus of human vascular endothelial cells. Genes Cells. 2005;10:1139–51.PubMedCrossRef
16.
Helmcke I, Heumuller S, Tikkanen R, et al. Identification of structural elements in Nox1 and Nox4 controlling localization and activity. Antioxid Redox Signal. 2009;11:1279–87.PubMedCrossRef
17.
Clempus RE, Sorescu D, Dikalova AE, et al. Nox4 is required for maintenance of the differentiated vascular smooth muscle cell phenotype. Arterioscler Thromb Vasc Biol. 2007;27:42–8.PubMedCrossRef
18.
• Takac I, Schroder K, Zhang L, et al.: The E-loop is involved in hydrogen peroxide formation by the NADPH oxidase Nox4. J Biol Chem 2011, 286:13304–13313. In this study, parts of the molecular basis of hydrogen peroxide formation by Nox4 are identified: Alterations in the E-loop switch the protein to superoxide formation. PubMedCrossRef
19.
Brandes RP, Schroder K. Differential vascular functions of Nox family NADPH oxidases. Curr Opin Lipidol. 2008;19:513–8.PubMedCrossRef
20.
• Hecker L, Vittal R, Jones T, et al.: NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury. Nat Med 2009, 15:1077–1081. It is demonstrated that Nox4 is induced in pulmonary fibrosis and promotes disease progression by the stimulation of myofibroblast differentiation. PubMedCrossRef
21.
Manea A. NADPH oxidase-derived reactive oxygen species: involvement in vascular physiology and pathology. Cell Tissue Res. 2010;342:325–39.PubMedCrossRef
22.
• Goettsch C, Goettsch W, Brux M, et al.: Arterial flow reduces oxidative stress via an antioxidant response element and Oct-1 binding site within the NADPH oxidase 4 promoter in endothelial cells. Basic Res Cardiol 2011, 106:551–561. This is one of the first studies to analyze the promoter of Nox4 and provide evidence for redox-dependent expression of the protein. PubMedCrossRef
23.
Duerrschmidt N, Stielow C, Muller G, et al. NO-mediated regulation of NAD(P)H oxidase by laminar shear stress in human endothelial cells. J Physiol. 2006;576:557–67.PubMedCrossRef
24.
• Lu X, Guo X, Wassall CD, et al.: Reactive oxygen species cause endothelial dysfunction in chronic flow overload. J Appl Physiol 2011, 110:520–527. High flow rates induce Nox2 and Nox4 in pigs, and antioxidative therapy blocks flow-induced remodeling, showing that redox-regulation in a large animal is involved in physiological remodeling processes. PubMedCrossRef
25.
• Schuhmacher S, Foretz M, Knorr M, et al.: α1AMP-activated protein kinase preserves endothelial function during chronic angiotensin II treatment by limiting Nox2 upregulation. Arterioscler Thromb Vasc Biol 2011, 31:560–566. A link between metabolic control and oxidative stress is provided by the demonstration that AMPK1α acts to limit Nox-dependent ROS formation in murine vessels. PubMedCrossRef
26.
Wang S, Zhang M, Liang B, et al. AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res. 2010;106:1117–28.PubMedCrossRef
27.
• Stanic B, Katsuyama M, Miller FJ Jr: An oxidized extracellular oxidation-reduction state increases Nox1 expression and proliferation in vascular smooth muscle cells via epidermal growth factor receptor activation. Arterioscler Thromb Vasc Biol 2010, 30:2234–2241. By a simple alteration in the extracellular concentration of cysteine to cystine, it is demonstrated that the redox milieu affects cellular signaling. The increase in the extracellular redox potential resulted in the induction of intracellular oxidizing enzymes. PubMedCrossRef
28.
Vasa-Nicotera M, Chen H, Tucci P, et al. miR-146a is modulated in human endothelial cell with aging. Atherosclerosis. 2011;217:326–30.PubMedCrossRef
29.
• Fu Y, Zhang Y, Wang Z, et al.: Regulation of NADPH oxidase activity is associated with miRNA-25-mediated NOX4 expression in experimental diabetic nephropathy. Am J Nephrol 2010, 32:581–589. The mechanism of diabetes-induced Nox4 expression is identified and related to a microRNA. PubMedCrossRef
30.
Kikuchi H, Kuribayashi F, Kiwaki N, et al. GCN5 regulates the superoxide-generating system in leukocytes via controlling gp91-phox gene expression. J Immunol. 2011;186:3015–22.PubMedCrossRef
31.
•• Schröder K, Kohnen A, Aicher A, et al.: NADPH oxidase Nox2 is required for hypoxia-induced mobilization of endothelial progenitor cells. Circ Res 2009, 105:537–544. It is identified that erythropoietin signaling in the bone marrow requires Nox2-dependent inactivation of the phosphatase SHP-2. This process is involved in vascular repair after carotid artery injury. PubMedCrossRef
32.
Sharma P, Chakraborty R, Wang L, et al. Redox regulation of interleukin-4 signaling. Immunity. 2008;29:551–64.PubMedCrossRef
33.
Liu RM, Choi J, Wu JH, et al. Oxidative modification of nuclear mitogen-activated protein kinase phosphatase 1 is involved in transforming growth factor beta1-induced expression of plasminogen activator inhibitor 1 in fibroblasts. J Biol Chem. 2010;285:16239–47.PubMedCrossRef
34.
Nakamura Y, Patrushev N, Inomata H, et al. Role of protein tyrosine phosphatase 1B in vascular endothelial growth factor signaling and cell-cell adhesions in endothelial cells. Circ Res. 2008;102:1182–91.PubMedCrossRef
35.
Tabet F, Schiffrin EL, Callera GE, et al. Redox-sensitive signaling by angiotensin II involves oxidative inactivation and blunted phosphorylation of protein tyrosine phosphatase SHP-2 in vascular smooth muscle cells from SHR. Circ Res. 2008;103:149–58.PubMedCrossRef
36.
Zimmerman MC, Takapoo M, Jagadeesha DK, et al. Activation of NADPH oxidase 1 increases intracellular calcium and migration of smooth muscle cells. Hypertension. 2011;58:446–53.PubMedCrossRef
37.
• Amberg GC, Earley S, Glapa SA: Local regulation of arterial L-type calcium channels by reactive oxygen species. Circ Res 2010, 107:1002–1010. This study identifies L-type calcium channels as an NADPH oxidase–modified redox target. It links Nox proteins to a direct, redox-dependent control of cerebral vascular tone. PubMedCrossRef
38.
Shimokawa H, Morikawa K. Hydrogen peroxide is an endothelium-derived hyperpolarizing factor in animals and humans. J Mol Cell Cardiol. 2005;39:725–32.PubMedCrossRef
39.
Larsen BT, Bubolz AH, Mendoza SA, et al. Bradykinin-induced dilation of human coronary arterioles requires NADPH oxidase-derived reactive oxygen species. Arterioscler Thromb Vasc Biol. 2009;29:739–45.PubMedCrossRef
40.
•• Ray R, Murdoch CE, Wang M, et al.: Endothelial Nox4 NADPH oxidase enhances vasodilatation and reduces blood pressure in vivo. Arterioscler Thromb Vasc Biol 2011, 31:1368–1376. Endothelium-specific Nox4 transgenic mice are characterized. Remarkably, the increase in Nox4-dependent endothelial hydrogen peroxide formation improved vascular function and lowered the blood pressure. PubMedCrossRef
41.
Thomas SR, Chen K, Keaney Jr JF. Hydrogen peroxide activates endothelial nitric-oxide synthase through coordinated phosphorylation and dephosphorylation via a phosphoinositide 3-kinase-dependent signaling pathway. J Biol Chem. 2002;277:6017–24.PubMedCrossRef
42.
Burgoyne JR, Madhani M, Cuello F, et al. Cysteine redox sensor in PKGIa enables oxidant-induced activation. Science. 2007;317:1393–7.PubMedCrossRef
43.
Miller AA, Drummond GR, Schmidt HH, et al. NADPH oxidase activity and function are profoundly greater in cerebral versus systemic arteries. Circ Res. 2005;97:1055–62.PubMedCrossRef
44.
Ushio-Fukai M, Nakamura Y. Reactive oxygen species and angiogenesis: NADPH oxidase as target for cancer therapy. Cancer Lett. 2008;266:37–52.PubMedCrossRef
45.
Gorlach A, Diebold I, Schini-Kerth VB, et al. Thrombin activates the hypoxia-inducible factor-1 signaling pathway in vascular smooth muscle cells: Role of the p22(phox)-containing NADPH oxidase. Circ Res. 2001;89:47–54.PubMedCrossRef
46.
Tojo T, Ushio-Fukai M, Yamaoka-Tojo M, et al. Role of gp91phox (Nox2)-containing NAD(P)H oxidase in angiogenesis in response to hindlimb ischemia. Circulation. 2005;111:2347–55.PubMedCrossRef
47.
Urao N, Inomata H, Razvi M, et al. Role of nox2-Based NADPH oxidase in bone marrow and progenitor cell function involved in neovascularization induced by hindlimb ischemia. Circ Res. 2008;103:212–20.PubMedCrossRef
48.
Schroder K, Schutz S, Schloffel I, et al. Hepatocyte growth factor induces a proangiogenic phenotype and mobilizes endothelial progenitor cells by activating nox2. Antioxid Redox Signal. 2011;15:915–23.PubMedCrossRef
49.
Al-Shabrawey M, Bartoli M, El-Remessy AB, et al. Inhibition of NAD(P)H oxidase activity blocks vascular endothelial growth factor overexpression and neovascularization during ischemic retinopathy. Am J Pathol. 2005;167:599–607.PubMedCrossRef
50.
• Zhang M, Brewer AC, Schroder K, et al.: NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis. Proc Natl Acad Sci U S A 2010, 107:18121–18126. Characterization of Nox4 transgenic and Nox4 knockout mice revealed that the enzyme controls hypoxia-driven VEGF expression. In the case of pressure overload, Nox4 facilitates cardiac angiogenesis and thereby prevents transition to heart failure. PubMedCrossRef
51.
Haddad P, Dussault S, Groleau J, et al. Nox2-derived reactive oxygen species contribute to hypercholesterolemia-induced inhibition of neovascularization: effects on endothelial progenitor cells and mature endothelial cells. Atherosclerosis. 2011;217:340–9.PubMedCrossRef
52.
Garrido-Urbani S, Jemelin S, Deffert C, et al. Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARalpha mediated mechanism. PLoS One. 2011;6:e14665.PubMedCrossRef
53.
Ebrahimian TG, Heymes C, You D, et al. NADPH oxidase-derived overproduction of reactive oxygen species impairs postischemic neovascularization in mice with type 1 diabetes. Am J Pathol. 2006;169:719–28.PubMedCrossRef
54.
Schroder K, Helmcke I, Palfi K, et al. Nox1 mediates basic fibroblast growth factor-induced migration of vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2007;27:1736–43.PubMedCrossRef
55.
• Craige SM, Chen K, Pei Y, et al.: NADPH oxidase 4 promotes endothelial angiogenesis through endothelial nitric oxide synthase activation. Circulation 2011, 124:731–740. The angiogenic function of Nox4 endothelial–specific transgenic mice is characterized. Nox4 overexpression promotes angiogenesis in mice by increasing NO availability. PubMedCrossRef
56.
Forstermann U. Janus-faced role of endothelial NO synthase in vascular disease: uncoupling of oxygen reduction from NO synthesis and its pharmacological reversal. Biol Chem. 2006;387:1521–33.PubMedCrossRef
57.
Loot AE, Schreiber JG, Fisslthaler B, et al. Angiotensin II impairs endothelial function via tyrosine phosphorylation of the endothelial nitric oxide synthase. J Exp Med. 2009;206:2889–96.PubMedCrossRef
58.
• Chen CA, Wang TY, Varadharaj S, et al.: S-glutathionylation uncouples eNOS and regulates its cellular and vascular function. Nature 2010, 468:1115–1118. Glutathionylation, a redox-dependent oxidative modification, is identified as a novel mechanism of eNOS uncoupling, demonstrating a novel mechanism of how oxidative stress leads to a breakdown of NO formation. PubMedCrossRef
59.
Matsuno K, Yamada H, Iwata K, et al. Nox1 is involved in angiotensin II-mediated hypertension: a study in Nox1-deficient mice. Circulation. 2005;112:2677–85.PubMedCrossRef
60.
Gavazzi G, Banfi B, Deffert C, et al. Decreased blood pressure in NOX1-deficient mice. FEBS Lett. 2006;580:497–504.PubMedCrossRef
61.
Jung O, Schreiber JG, Geiger H, et al. gp91phox-containing NADPH oxidase mediates endothelial dysfunction in renovascular hypertension. Circulation. 2004;109:1795–801.PubMedCrossRef
62.
•• Violi F, Sanguigni V, Carnevale R, et al.: Hereditary deficiency of gp91(phox) is associated with enhanced arterial dilatation: results of a multicenter study. Circulation 2009, 120:1616–1622. This is the first report on the characterization of endothelium-dependent relaxation in patients with genetic loss of Nox2 activity. It is demonstrated that Nox2 also limits NO availability in humans. PubMedCrossRef
63.
• Pignatelli P, Carnevale R, Di Santo S, et al.: Inherited human gp91phox deficiency is associated with impaired isoprostane formation and platelet dysfunction. Arterioscler Thromb Vasc Biol 2011, 31:423–434. By the inclusion of patients with chronic granulomatous disease, it is demonstrated that Nox2 in humans controls redox processes in platelets as the formation of lipid peroxides. PubMedCrossRef
64.
•• Loukogeorgakis SP, van den Berg MJ, Sofat R, et al.: Role of NADPH oxidase in endothelial ischemia/reperfusion injury in humans. Circulation 2010, 121:2310–2316. With the inclusion of patients with mutations of the NADPH oxidase Nox2, it is demonstrated that the enzyme contributes to reperfusion-induced endothelial dysfunction after ischemia of the arm. PubMedCrossRef
65.
Hwang J, Saha A, Boo YC, et al. Oscillatory shear stress stimulates endothelial production of O2- from p47phox-dependent NAD(P)H oxidases, leading to monocyte adhesion. J Biol Chem. 2003;278:47291–8.PubMedCrossRef
66.
• Vecchione C, Carnevale D, Di Pardo A, et al.: Pressure-induced vascular oxidative stress is mediated through activation of integrin-linked kinase 1/betaPIX/Rac-1 pathway. Hypertension 2009, 54:1028–1034. The study provides direct evidence in mice that hypertension per se increases NADPH oxidase by stimulating the activity of Rac1. PubMedCrossRef
67.
Dikalova A, Clempus R, Lassegue B, et al. Nox1 overexpression potentiates angiotensin II-induced hypertension and vascular smooth muscle hypertrophy in transgenic mice. Circulation. 2005;112:2668–76.PubMedCrossRef
68.
Bendall JK, Rinze R, Adlam D, et al. Endothelial Nox2 overexpression potentiates vascular oxidative stress and hemodynamic response to angiotensin II: studies in endothelial-targeted Nox2 transgenic mice. Circ Res. 2007;100:1016–25.PubMedCrossRef
69.
Murdoch CE, om-Ruiz SP, Wang M, et al. Role of endothelial Nox2 NADPH oxidase in angiotensin II-induced hypertension and vasomotor dysfunction. Basic Res Cardiol. 2011;106:527–38.PubMedCrossRef
70.
Brandes RP, Takac I, Schroder K. No superoxide–no stress?: Nox4, the good NADPH oxidase! Arterioscler Thromb Vasc Biol. 2011;31:1255–7.PubMedCrossRef
71.
• Basuroy S, Tcheranova D, Bhattacharya S, et al.: Nox4 NADPH oxidase-derived reactive oxygen species, via endogenous carbon monoxide, promote survival of brain endothelial cells during TNF-alpha-induced apoptosis. Am J Physiol Cell Physiol 2011, 300:C256–C265. CO is reported to be an effector of Nox4-dependent signaling. CO is also characterized as a molecule inhibiting Nox4 activity in endothelial cells. PubMedCrossRef
72.
Peterson JR, Sharma RV, Davisson RL. Reactive oxygen species in the neuropathogenesis of hypertension. Curr Hypertens Rep. 2006;8:232–41.PubMedCrossRef
73.
Capone C, Faraco G, Park L, et al. The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. Am J Physiol Heart Circ Physiol. 2011;300:H397–407.PubMedCrossRef
74.
Harrison DG, Guzik TJ, Goronzy J, et al. Is hypertension an immunologic disease? Curr Cardiol Rep. 2008;10:464–9.PubMedCrossRef
75.
Fujii A, Nakano D, Katsuragi M, et al. Role of gp91phox-containing NADPH oxidase in the deoxycorticosterone acetate-salt-induced hypertension. Eur J Pharmacol. 2006;552:131–4.PubMedCrossRef
76.
Zhang A, Jia Z, Wang N, et al. Relative contributions of mitochondria and NADPH oxidase to deoxycorticosterone acetate-salt hypertension in mice. Kidney Int. 2011;80:51–60.PubMedCrossRef
77.
Zhang R, Harding P, Garvin JL, et al. Isoforms and functions of NAD(P)H oxidase at the macula densa. Hypertension. 2009;53:556–63.PubMedCrossRef
78.
Cabral PD, Garvin JL. Luminal flow regulates NO and O2(−) along the nephron. Am J Physiol Renal Physiol. 2011;300:F1047–53.PubMedCrossRef
79.
Carlstrom M, Lai EY, Ma Z, et al. Role of NOX2 in the regulation of afferent arteriole responsiveness. Am J Physiol Regul Integr Comp Physiol. 2009;296:R72–9.PubMedCrossRef
80.
• Niu XL, Madamanchi NR, Vendrov AE, et al.: Nox activator 1: a potential target for modulation of vascular reactive oxygen species in atherosclerotic arteries. Circulation 2010, 121:549–559. This study established a direct role of Noxa1, a cofactor of NADPH oxidases, in vascular pathology. PubMedCrossRef
81.
Guzik TJ, Chen W, Gongora MC, et al. Calcium-dependent NOX5 nicotinamide adenine dinucleotide phosphate oxidase contributes to vascular oxidative stress in human coronary artery disease. J Am Coll Cardiol. 2008;52:1803–9.PubMedCrossRef
82.
Judkins CP, Diep H, Broughton BR, et al. Direct evidence of a role for Nox2 in superoxide production, reduced nitric oxide bioavailability, and early atherosclerotic plaque formation in ApoE−/− mice. Am J Physiol Heart Circ Physiol. 2010;298:H24–32.PubMedCrossRef
83.
Kirk EA, Dinauer MC, Rosen H, et al. Impaired superoxide production due to a deficiency in phagocyte NADPH oxidase fails to inhibit atherosclerosis in mice. Arterioscler Thromb Vasc Biol. 2000;20:1529–35.PubMedCrossRef
84.
Hsich E, Segal BH, Pagano PJ, et al. Vascular effects following homozygous disruption of p47(phox): an essential component of NADPH oxidase. Circulation. 2000;101:1234–6.PubMed
85.
Sheehan AL, Carrell S, Johnson B, et al. Role for Nox1 NADPH oxidase in atherosclerosis. Atherosclerosis. 2011;216:321–6.PubMedCrossRef
86.
• Bae YS, Lee JH, Choi SH, et al.: Macrophages generate reactive oxygen species in response to minimally oxidized low-density lipoprotein: Toll-like receptor 4- and spleen tyrosine kinase-dependent activation of NADPH oxidase 2. Circ Res 2009, 104:210–8, 21p. The tyrosine kinase Sky is established as a Nox2-dependent redox target in macrophages. This work associates lipoprotein with redox regulation in these cells.
87.
• Lee CF, Qiao M, Schroder K, et al.: Nox4 is a novel inducible source of reactive oxygen species in monocytes and macrophages and mediates oxidized low density lipoprotein-induced macrophage death. Circ Res 2010, 106:1489–1497. It is demonstrated that Nox4 is induced in macrophages in response to oxidized LDL (oxLDL) and mediates oxLDL-dependent signaling. PubMedCrossRef
88.
Pedruzzi E, Guichard C, Ollivier V, et al. NAD(P)H oxidase Nox-4 mediates 7-ketocholesterol-induced endoplasmic reticulum stress and apoptosis in human aortic smooth muscle cells. Mol Cell Biol. 2004;24:10703–17.PubMedCrossRef
89.
Thomas M, Gavrila D, McCormick ML, et al. Deletion of p47phox attenuates angiotensin II-induced abdominal aortic aneurysm formation in apolipoprotein E-deficient mice. Circulation. 2006;114:404–13.PubMedCrossRef
90.
Gavazzi G, Deffert C, Trocme C, et al. NOX1 deficiency protects from aortic dissection in response to angiotensin II. Hypertension. 2007;50:189–96.PubMedCrossRef
91.
Lee MY, San MA, Mehta PK, et al. Mechanisms of vascular smooth muscle NADPH oxidase 1 (Nox1) contribution to injury-induced neointimal formation. Arterioscler Thromb Vasc Biol. 2009;29:480–7.PubMedCrossRef
92.
• Conrad M, Sandin A, Forster H, et al.: 12/15-lipoxygenase-derived lipid peroxides control receptor tyrosine kinase signaling through oxidation of protein tyrosine phosphatases. Proc Natl Acad Sci U S A 2010, 107:15774–15779. It is demonstrated that by direct modification of cysteines, lipid peroxides are just as able as hydrogen peroxide to induce redox regulation by phosphatase inhibition. PubMedCrossRef
93.
Drummond GR, Selemidis S, Griendling KK, et al. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov. 2011;10:453–71.PubMedCrossRef
94.
• Sedeek M, Callera G, Montezano A, et al.: Critical role of Nox4-based NADPH oxidase in glucose-induced oxidative stress in the kidney: implications in type 2 diabetic nephropathy. Am J Physiol Renal Physiol 2010, 299:F1348–F1358. A specific Nox inhibitor is used to prevent diabetes-induced renal fibrosis in mice. PubMedCrossRef
95.
Vendrov AE, Madamanchi NR, Niu XL, et al. NADPH oxidases regulate CD44 and hyaluronic acid expression in thrombin-treated vascular smooth muscle cells and in atherosclerosis. J Biol Chem. 2010;285:26545–57.PubMedCrossRef
96.
• Kuhns DB, Alvord WG, Heller T, et al.: Residual NADPH oxidase and survival in chronic granulomatous disease. N Engl J Med 2010, 363:2600–2610. On the basis of a large cohort of patients with NADPH oxidase mutations, this study correlates ROS production of leukocytes with survival. It demonstrates that a slight inhibition of Nox activity does not increase mortality. A strong inverse correlation between ROS production and mortality is reported. PubMedCrossRef
97.
Zhou Q, Liao JK. Pleiotropic effects of statins. Basic research and clinical perspectives. Circ J. 2010;74:818–26.PubMedCrossRef
98.
Antoniades C, Bakogiannis C, Tousoulis D, et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation. 2010;122:S66–73.PubMedCrossRef
Metadata
Title
The Nox Family of NADPH Oxidases: Friend or Foe of the Vascular System?
Authors
Ina Takac
Katrin Schröder
Ralf P. Brandes
Publication date
01-02-2012
Publisher
Current Science Inc.
Published in
Current Hypertension Reports / Issue 1/2012
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI
https://doi.org/10.1007/s11906-011-0238-3

Other articles of this Issue 1/2012

Current Hypertension Reports 1/2012 Go to the issue

Vascular Mechanisms (F Ruschitzka, Section Editor)

MicroRNAs in Hypertension: Mechanisms and Therapeutic Targets

Pathogenesis of Hypertension: Genetic and Environmental Factors (DT O’Connor, Section Editor)

Disorders of Blood Pressure Regulation—Role of Catecholamine Biosynthesis, Release, and Metabolism

Pathogenesis of Hypertension: Genetic and Environmental Factors (DT O’Connor, Section Editor)

Epinephrine and the Metabolic Syndrome

Pathogenesis of Hypertension: Genetic and Environmental Factors (DT O’Connor, Section Editor)

Between Candidate Genes and Whole Genomes: Time for Alternative Approaches in Blood Pressure Genetics

Pathogenesis of Hypertension: Genetic and Environmental Factors (D O’Connor, Section Editor)

Target Organ Damage in African American Hypertension: Role of APOL1

Vascular Mechanisms (FT Ruschitzka, Section Editor)

M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits